A retrospective cohort study to investigate the incidence of cachexia in pancreatic cancer patients
- Conditions
- Pancreatic Cancer
- Registration Number
- JPRN-UMIN000034972
- Lead Sponsor
- ONO PHARMACEUTICAL CO., LTD.
- Brief Summary
A total of 150 patients were registered. Base cachexia occurred in 50% of patients. Follow-up cachexia occurred in 32% within 12 weeks of starting first-line chemotherapy, reaching 64% at 1 year. Overall survival was not significantly different between patients with and without follow-up cachexia. Appetite loss, fatigue, nausea, and diarrhea were more frequent in patients with follow-up cachexia than in those without follow-up cachexia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Not provided
Patients who meet at least one of the following exclusion criteria are not included. 1) Patient who underwent surgical operation of the gastrointestinal tract within the last 6 months starting from the beginning day of the first systemic chemotherapy excluding stent placement in the duodenum or gastrojejunostomy 2) Patients with simultaneously active, double cancer (Stage I intraepithelial carcinoma, intramucosal carcinoma, superficial bladder carcinoma, or other cancers without recurrence for 5 years or more can be registered) 3) Patients with missing of body weight data over 12 weeks in the medical consultation period after the beginning of initial systemic chemotherapy 4) Patients who underwent puncture for ascitic fluid at the beginning of initial systemic chemotherapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method